Exenatide suppresses 1,2-dimethylhydrazine-induced colon cancer in diabetic mice: Effect on tumor angiogenesis and cell proliferation

Biomedicine and Pharmacotherapy

Volumn 82, Issue , 2016, Pages 106-116

  Tawfik, Mona K ^a   Mohamed, Magda I ^b  

^a Suez Canal University Faculty of Medicine   (Egypt)

^b Suez Canal University   (Egypt)

Author keywords

Angiogenesis; Cell proliferation; Colonic neoplasm; Diabetes mellitus; Exenatide; Inflammation

Indexed keywords

1,2 DIMETHYLHYDRAZINE; CD34 ANTIGEN; CISPLATIN; EXENDIN 4; KI 67 ANTIGEN; CYCLOOXYGENASE 2; INTERLEUKIN 6; MESSENGER RNA; PEPTIDE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VENOM;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROLIFERATION; COLON CARCINOGENESIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; ANIMAL; BLOOD; BODY WEIGHT; CHEMICALLY INDUCED; COLON; COLONIC NEOPLASMS; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; SURVIVAL ANALYSIS; VASCULARIZATION;

1,2-DIMETHYLHYDRAZINE; ANIMALS; ANTIGENS, CD34; BODY WEIGHT; CELL PROLIFERATION; CISPLATIN; COLON; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; DIABETES MELLITUS, EXPERIMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; INTERLEUKIN-6; KI-67 ANTIGEN; MALE; MICE; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; RNA, MESSENGER; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VENOMS;

EID: 84965013500     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.05.005     Document Type: Article

References (54)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M. Cancer statistics. Cancer J. Clin. 2009, 59:225-249. 10.3322/caac.20006.
2. LaMont J., O'Gorman A. Experimental colon cancer. Gastroenterol. J. 1978, 75:1157-1169. PMID: 213347.
3. Campbell P.T., Deka A., Jacobs E.J., Newton C.C., Hildebrand J.S., Mc-Cullough M.L., et al. Prospective study reveals associations between colorectal cancer and type 2 diabetes mellitus or insulin use in men. Gastroenterology 2010, 139:1138-1146. 10.1053/j.gastro.2010 06.072.
4. Sen S., He Y., Kanasaki K. Cancer biology in diabetes. J. Diab. Invest. 2014, 5:251-264. 10.1111/jdi.12208.
5. Grivennikov S., Greten F., Karin M. Immunity, inflammation, and cancer. Cell J. 2010, 140:883-899. 10.1016/j.cell.2010.01.025.
6. Liang J.F., Wang H.K., Xiao H., Li N., Cheng C., Zhao Y., et al. Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer. J. Exp. Clin. Cancer Res. 2010, 29:71-82. 10.1186/1756-9966-29-71.
7. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J. Nutr. 2001, 131:3109-3120.
8. Green B., Hand K., Dougan J., McDonnell B., Cassidy R., Grieve D. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch. Biochem. Biophys. 2008, 478:136-142. 10.1016/j.abb.2008.08.001.
9. Ussher J., Drucker D. Cardiovascular biology of the incretin system. Endocr. Rev. 2012, 33:187-215. 10.1210/er.2011-1052.
10. Shannon R., Angeli F. Beyond glucose: cardiovascular effects of incretins and dipeptidyl peptidase-4 substrates. Eur. Heart J. 2012, 14:B14-B21. 10.1093/eurheartj/sus001.
11. Oyama J., Higashi Y., Node K. Do incretins improve endothelial function?. Cardiovas. Diabetol. 2014, 13:21-29. 10.1186/1475-2840-13-21.
12. Chaudhuri A., Ghanim H., Vora M., Sia C.L., Korzeniewski K., Dhindsa S., et al. Exenatide exerts a potent anti-inflammatory effect. J. Clin. Endocrinol. Metab. 2012, 97:198-207. 10.1210/jc.2011-1508.
13. Hatwal A. Inflammation and incretins. Ind. J. Endocrinol. Metab. 2012, 16:S239-S241. 10.4103/2230-8210.104049.
14. Sheikh A. Direct cardiovascular effects of glucagon like peptide-1. Diabetol. and Metab. Syndr. 2013, 5:47-60. 10.1186/1758-5996-5-47.
15. Körner E., Christ D. Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications. Front. Endocrinol. 2012, 3:1-7. 10.3389/fendo.2012.00158.
16. Yi F., Sun J., Lim G., Fantus I., Brubaker P., Jin T. Crosstalk between the insulin and Wnt signaling pathways: evidence from intestinal endocrine L cells. Endocrinol. J. 2008, 149:2341-2351. 10.1210/en.2007-1142.
17. Srinivasan K., Viswanad B., Asrat L., Kaul C.L., Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol. Res. 2005, 52:313-320. 10.1016/j.phrs.2005.05.004.
18. Colussi S., Fiumicino A., Giuliani S., Rosini P. 1,2-di-methylhydrazine-induced colon carcinoma and lymphoma in msh2-/- mice. J. Natl. Cancer Inst. 2001, 93:1534-1540. 10.1093/jnci/93.20.1534.
19. Gong N., Ma A., Zhang L., Luo X., Zhang Y., Xu M., et al. Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity. Br. J. Pharmacol. 2011, 163:399-412. 10.1111/j.1476-5381.2011.01227.
20. Vogler G.A. Anesthesia and analgesia 2006, 627-695. The Laboratory Rat Elsevier Academic Press, New York. M.A. Suckow, S. Weisbroth, C.L. Franklin (Eds.).
21. Perše M., Cerar A. Morphological and molecular alterations in 1,2di-methylhydrazine and azoxymethane induced colon carcinogenesis in rats. J. Biomed. Biotechnol. 2011, 2011:473964-473978. 10.1155/2011/473964.
22. Pfaffl M. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29:e45.
23. Wu Q., Wang H., Zhao X., Shi Y., Jin M., Wan B., et al. Identification of G-protein-coupled receptor 120 as a tumor-promoting receptor that induces angiogenesis and migration in human colorectal carcinoma. Oncogene 2013, 32:5541-5550. 10.1038/onc.2013.264.
24. Hata K., Kubota M., Shimizu M., Moriwaki H., Kuno T., Tanaka T., et al. Monosodium glutamate-induced diabetic mice are susceptible to azoxymethane-induced colon tumorigenesis. Carcinogenesis 2012, 33:702-707. 10.1093/carcin/bgr323.
25. Jeon J.Y., Jeong D.H., Park M.G., Lee J.W., Chu S.H., Park J.H., et al. Impact of diabetes on oncologic outcome of colorectal cancer patients: colon vs rectal cancer. PLoS One 2013, 8:e55196. 10.1371/journal.pone.0055196.
26. Femia A., Raimondi L., Maglieri G., Lodovici M., Mannucci E., Caderni G. Long-term treatment with sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats. Int. J. Cancer 2013, 133:2498-2503. 10.1002/ijc.28260.
27. Umesalma S., Sudhandiran G. Ellagic acid prevents rat colon carcinogenesis induced by 1,2dimethyl hydrazine through inhibition of AKT-phosphoinositide-3 kinase pathway. Eur. J. Pharmacol. 2011, 660:249-258. 10.1016/j.ejphar.2011.03.036.
28. Shen H., Tergaoankar V. NF-kappa B signaling in carcinogenesis and as potential molecular target for cancer therapy. Apoptosis J. 2009, 14:348-363. 10.1007/s10495-009-0315-0.
29. Handelsman Y., LeRoith D., Bloomgarden Z.T., Dagogo-Jack S., Einhorn D., Garber A.J., et al. Diabetes and cancer-an AACE/ACE consensus statement. Endocr. Pract. 2013, 19:675-693. 10.4158/EP13248.CS.
30. Roelofs H., Te Morsche R., van Heumen B., Nagengast F., Peters W. Over-expression of COX-2 mRNA in colorectal cancer. BMC Gastroenterol. 2014, 2:1-6. 10.1186/1471-230X-14-1.
31. Hamiza O., Rehman M., Tahir M., Khan R., Khan A., Lateef A., et al. Amelioration of 1,2dimethylhydrazine (DMH) induced colon oxidative stress, inflammation and tumor promotion response by tannic acid in wistar rats. Asian Pac. J. Cancer Prev. 2012, 13:4393-4402.
32. Huang X., Chen J. Obesity, the PI3 K/Akt signal pathway and colon cancer. Obes. Rev. 2009, 10:610-616. 10.1111/j.1467-789X.2009.00607.
33. Giovannucci E., Harlan D.M., Archer M.C., Bergenstal R.M., Gapstur S.M., Habel L.A., et al. Diabetes and cancer: a consensus report. Diabetes Care 2010, 33:1674-1685. 10.2337/dc10-0666.
34. Giacchetti S., Perpoint B., Zidani R., Le Bail N., Faggiuolo R., Focan C., et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 2000, 18:136-147.
35. Koehler J., Kain T., Drucker D. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. Endocrinol. J. 2011, 152:3362-3372. 10.1210/en.2011-1201.
36. Campbell J., Drucker D. Pharmacology, physiology and mechanisms of incretin hormone action. Cell Metab. 2013, 17:819-837. 10.1016/j.cmet.2013.04.008.
37. Li Y., Perry T., Kindy M.S., Harvey B.K., Tweedie D., Holloway H.W., et al. 1GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:1285-1290. 10.1073/pnas.0806720106.
38. Shiraki A., Oyama J., Komoda H., Asaka M., Komatsu A., Sakuma M., et al. The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis J. 2012, 221:375-382. 10.1016/j.atherosclerosis.
39. Kissow H., Hartmann B., Holst J., Poulsen S. Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis. Gut J. 2013, 62:1724-1733. 10.1136/gutjnl-2012-303280.
40. Hadjiyanni I., Siminovitch K.A., Danska J.S., Drucker D.J. Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells. Diabetologia 2010, 53:730-740. 10.1007/s00125-009-1643-x.
41. Barnes P.J., Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 1997, 336:1066-1071. 10.1056/NEJM199704103361506.
42. Xue S.1, Wasserfall C.H., Parker M., Brusko T.M., McGrail S., McGrail K., Moore M., Campbell-Thompson M., Schatz D.A., Atkinson M.A., Haller M.J. Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency. Ann. N. Y. Acad. Sci. 2008, 1150:152-156. 10.1196/annals.1447.049.
43. Wu J.D., Xu X.H., Zhu J., Ding B., Du T.X., Gao G., Mao X.M., Ye L., Lee K.O., Ma J.H. Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus. Diabetes Technol. Ther. 2011, 13:143-148. 10.1089/dia.2010.0048.
44. Cao H., Jin C., Huang D., Liu C., Sun D., Tan C., et al. Changes in serum IGF-1 level and tumor VEGF expression in mice with colorectal cancer under hyperglycemic conditions. Mol. Med. Rep. 2013, 26:1361-1365. 10.3892/mmr.2013.1339.
45. Ezzat V.A., Duncan E.R., Wheatcroft S.B., Kearney M.T. The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease. Diabetes Obes. Metab. 2008, 10:198-211. 10.1111/j.1463-1326.2007.00709.x.
46. Grulich-Henn J., Ritter J., Mesewinkel S., Heinrich U., Bettendorf M., Preissner K.T. Transport of insulin-like growth factor-1 across endothelial cell monolayers and its binding to the subendothelial matrix. Exp. Clin. Endocrinol. Diabetes 2002, 110(2):67-73. 10.1055/s-2002-23488.
47. Dai J., Wan S., Zhou F., Myers R.E., Guo X., Li B., et al. Genetic polymorphism in a VEGF-independent angiogenesis gene ANGPT1 and overall survival of colorectal cancer patients after surgical resection. PLoS One 2012, 7:e34758. 10.1371/journal.Pone.0034758.
48. Oh S.Y., Kwon H., Kim S.H., Lee S., Lee J.H., Hwang J., et al. The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer. B. M. C. Cancer 2013, 13:43-51. 10.1186/1471-2407-13-43.
49. Bhattacharyya S., Krukovets K., Nestor I., Li J., Adognravi O. Novel tissue-specific mechanism of regulation of angiogenesis and cancer growth in response to hyperglycemia. J. Am. Heart Assoc. 2012, 1:e005967. 10.1161/JAHA.112.005967.
50. Stenina O.I. Regulation of vascular genes by glucose. Curr. Pharm. Des. 2005, 11:2367-2381. 10.2174/1381612054367283.
51. Bhattacharyya S., Marinic T.E., Krukovets I., Hoppe G., Stenina O.I. Cell type specific post-transcriptional regulation of production of the potent antiangiogenic and proatherogenic protein thrombospondin-1 by high glucose. J. Biol. Chem. 2008, 283:5699-5707. 10.1074/jbc.M706435200.
52. Ligumsky H., Wolf I., Israeli S., Haimsohn M., Ferber S., Karasik A., et al. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. Breast Cancer Res. Treat. 2012, 132:449-461. 10.1007/s10549-011-1585-0.
53. Luciani P., Deledda C., Peri A. Exendin-4 induces cell adhesion and differentiation and counteracts the invasive potential of human neuroblastoma cells. PLoS One 2013, 8:e71716. 10.1371/journal.pone.
54. Nieminen A., Partanen J., Klefstrom J. c-Myc blazing a trail of death: coupling of the mitochondrial and death receptor apoptosis pathways by c-Myc. Cell Cycle 2007, 6:2464-2472. 10.4161/cc.6.20.4917.